Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain

被引:39
作者
Cirioni, Oscar
Ghiselli, Roberto
Silvestri, Carmela
Kamysz, Wojciech
Orlando, Fiorenza
Mocchegiani, Federico
Di Matteo, Fabio
Riva, Alessandra
Lukasiak, Jerzy
Scalise, Giorgio
Saba, Vittorio
Giacometti, Andrea
机构
[1] Univ Politecn Marche, Inst Infect Dis & Publ Hlth, Ancona, Italy
[2] Univ Politecn Marche, Dept Gen Surg, INRCA, IRRCS, Ancona, Italy
[3] Med Univ Gdansk, Fac Pharm, Gdansk, Poland
[4] IRRCS, INRCA, Dept Res, Expt Anim Models Aging Units, Ancona, Italy
关键词
D O I
10.1128/AAC.01576-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
An experimental study has been performed to compare the in vitro activity and the in vivo efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. In vitro experiments included MIC determination, time-kill, and synergy studies. For in vivo studies, a mouse model of sepsis has been used. The main outcome measures were bacterial lethality, quantitative blood cultures, and plasma levels of lipopolysaccharide, tumor necrosis factor alpha, and interleukin-6. The combination of tachyplesin III or colistin with imipenem showed in vitro synergistic interaction. A significant increase in efficacy was also observed in vivo: combination-treated groups had significantly lower levels of bacteremia than did groups treated with a single agent. Tachyplesin III combined with imipenem exhibited the highest efficacy on all main outcome measurements. These results highlight the potential usefulness of these combinations and provide therapeutic alternatives for serious infections caused by gram-negative bacteria in the coming years.
引用
收藏
页码:2005 / 2010
页数:6
相关论文
共 27 条
  • [1] THE PATHOGENESIS OF SEPSIS
    BONE, RC
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) : 457 - 469
  • [2] ANTIMICROBIAL PEPTIDES - A FAMILY OF WOUND HEALERS
    CANNON, M
    [J]. NATURE, 1987, 328 (6130) : 478 - 478
  • [3] Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents
    Carmeli, Y
    Troillet, N
    Eliopoulos, GM
    Samore, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1379 - 1382
  • [4] Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia
    Chamot, E
    El Amari, EB
    Rohner, P
    Van Delden, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) : 2756 - 2764
  • [5] CHRISTENSEN T, 1979, ACTA CHEM SCAND B, V33, P763, DOI 10.3891/acta.chem.scand.33b-0763
  • [6] BETA-LACTAM ANTIBIOTICS POTENTIATE MAGAININ-2 ANTIMICROBIAL ACTIVITY INVITRO AND INVIVO
    DARVEAU, RP
    CUNNINGHAM, MD
    SEACHORD, CL
    CASSIANOCLOUGH, L
    COSAND, WL
    BLAKE, J
    WATKINS, CS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1153 - 1159
  • [7] Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
  • [8] SOLID-PHASE PEPTIDE-SYNTHESIS UTILIZING 9-FLUORENYLMETHOXYCARBONYL AMINO-ACIDS
    FIELDS, GB
    NOBLE, RL
    [J]. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1990, 35 (03): : 161 - 214
  • [9] In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients
    Giacometti, A
    Cirioni, O
    Kamysz, W
    D'Amato, G
    Silvestri, C
    Del Prete, MS
    Licci, A
    Riva, A
    Lukasiak, J
    Scalise, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 1249 - 1252
  • [10] Giamarellou Helen, 2006, Expert Rev Anti Infect Ther, V4, P601, DOI 10.1586/14787210.4.4.601